Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets

Blood

Volumn 99, Issue 6, 2002, Pages 2054-2059

  Curtis, Brian R ^a,b,c   Swyers, Julia ^a,b,c   Divgi, Ajit ^a,b,c   McFarland, Janice G ^a,b,c   Aster, Richard H ^a,b,c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ST LUKE S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGH RISK POPULATION; HUMAN; INHIBITION KINETICS; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK ASSESSMENT; THROMBOCYTOPENIA;

EID: 0037085779     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.2054     Document Type: Article

References (35)

1. Platelet GPIIb/IIIa blockers
2. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment
3. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
4. Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb/IIIa complex receptor
5. Pharmaco-dynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade
6. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization: The EPILOG Investigators
7. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
8. Complementary clinical benefits of coronaryartery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
9. Occurrence and clinical significance of thrombocytopenia of a population of high-risk percutaneous coronary revascularization
10. Acute profound thrombocytopenia following C73 Fab (abciximab) therapy: Case reports, review of the literature, and implications for therapy
11. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade
12. Effect of abciximab readministration in coronary intervention
13. Readministration of abciximab: Interim report of the ReoPro readministration registry
14. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors
15. Platelet activation as a potential mechanism of GPIIb/IIIa inhibitor-induced thrombocytopenia
16. Antibodies associated with sulfonamide-induced immune thrombocytopenia react preferentially with calcium-dependent epitopes on the glycoprotein IIb/IIIa complex
17. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa
18. Incidence of anti-mouse antibodies in thrombocytopenic patients with autoimmune disorders
19. Incidence of autoantibodies to GPIIb/IIIa in chronic autoimmune thrombocytopenic purpura may be overestimated by the MAIPA
20. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?
21. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
22. Diagnostic testing for heparin-induced thrombocytopenia (HIT): An enhanced platelet factor 4 complex enzyme linked immunosorbent assay (PF4 ELISA)
23. Heparin-induced thrombocytopenia and its treatment
24. Anti-gammaglobulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies
25. Anti-Fab antibodies in humans; predominance of minor immunoglobulin G subclasses in rheumatoid arthritis
26. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions
27. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes
28. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimeric antibody
29. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
30. Effect of glycoprotein IIb/IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement
31. Evaluation of platelet membrane glycoproteins in coronary artery disease: Consequences for diagnosis and therapy
32. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris
33. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty
34. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy
35. Platelet surface IgG in patients receiving infusions of Fab chimeric monoclonal antibody to glycoprotein IIb/IIIa